점막용 분무 디바이스 시장 : 제품 유형, 기술, 최종사용자 - 세계 예측(2024-2032년)

The Mucosal Atomization Device Market size will grow at 7.4% CAGR during 2024-2032, driven by the increasing prevalence of chronic diseases. According to the WHO report, the proportion of annual deaths attributed to non-communicable diseases (NCDs) has risen to nearly three-quarters of all deaths. If this trend persists, it is projected to reach approximately 86% worldwide by 2048.

Mucosal atomization devices provide a non-invasive and convenient way to administer medications, offering advantages such as rapid absorption and improved patient compliance. These devices are particularly valuable in managing chronic conditions that require frequent medication administration, contributing to better disease management and enhanced patient outcomes.

Advanced atomization technologies include improvements in nozzle design for more precise drug delivery, incorporation of smart features for dosage control and monitoring, and the development of portable and user-friendly devices. Such innovations are crucial in meeting the increasing demand for minimally invasive drug delivery methods across various medical applications, thereby shaping the future of healthcare delivery.

The mucosal atomization device industry is classified based on product type, technology, end-user and region.

The laryngo tracheal atomization devices segment will gain prominence through 2032, owing to its ability to deliver medications directly into the larynx and trachea, ensuring rapid absorption and therapeutic efficacy. LTA devices are particularly valuable in emergency medicine and intensive care units (ICUs) where immediate drug administration is crucial for patient stabilization. The ability of LTA devices to deliver medications accurately and efficiently enhances patient outcomes, making them essential tools in modern healthcare settings.

The gas propelled atomization devices segment will grow at a rapid pace through 2032, as they ensure uniform distribution and enhanced bioavailability. Gas propelled atomization technology is preferred for its reliability and versatility in delivering a wide range of medications, including vaccines, antibiotics, and analgesics. The precise control over dosage and particle size offered by these devices is critical in optimizing therapeutic outcomes and reducing treatment times.

Europe mucosal atomization device industry will grow at a steady pace through 2032, driven by advanced healthcare infrastructure and increasing adoption of innovative medical technologies. Countries like Germany, France, and the UK are at the forefront of market growth, supported by robust healthcare spending and favorable regulatory policies. The rising prevalence of chronic diseases and the aging population further fuel the demand for efficient drug delivery solutions. Moreover, ongoing R&D activities in pharmaceuticals and medical devices catalyze the introduction of advanced atomization devices in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of respiratory illnesses
    • 3.2.1.2 Expanding adoption of intranasal drug delivery systems
    • 3.2.1.3 Surging demand for safer medication delivery solutions
    • 3.2.1.4 Precise drug delivery through mucosal atomization devices
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory approval procedures
    • 3.2.2.2 Limited compatibility with different types of medications
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Nasal atomization devices
• 5.3 Fiber optic atomization devices
• 5.4 Laryngo tracheal atomization devices
• 5.5 Bottle atomizers

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Gas propelled atomization devices
• 6.3 Electrical atomization devices

Chapter 7 Market Estimates and Forecast, By End User, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgery centers
• 7.4 Specialty clinics

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends, by region
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 South Korea
  • 8.4.5 Australia
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 UAE
  • 8.6.3 Saudi Arabia
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Becton, Dickinson and Co.
• 9.2 BTME Group Ltd. (Medtree)
• 9.3 BVM Meditech Pvt. Ltd.
• 9.4 Cook Medical, Inc.
• 9.5 DeVilbiss Healthcare LLC
• 9.6 Intersurgical Ltd.
• 9.7 Kurve Therapeutics
• 9.8 Life-Assist Inc.
• 9.9 Medica Holdings, LLC
• 9.10 Medspray
• 9.11 Pulmodyne, Inc.
• 9.12 Teleflex Inc.